vaccine-trials Downloads
6 downloads found
Immunogenicity assays play a vital role in evaluating the safety and efficacy of vaccines by measuring the immune response induced in vaccinated individuals, and serve as crucial tools in vaccine development, clinical trials, licensure, and post-marketing surveillance. Various methods are employed in vaccine immunogenicity assays, ranging from traditional techniques like LBAs to advanced ...
The Maxim HIV-1 Limiting Antigen-Avidity EIA is an in-vitro quantitative limiting antigen (LAg) avidity enzyme immunoassay for distinguishing recent HIV-1 infections from those which are long-term. Persons with recently acquired HIV-1 infections typically exhibit HIV-1 specific IgG populations with higher proportions of lower avidity IgG than those with long-term infections which typically ...
The Maxim HIV-1 Limiting Antigen-Avidity Dried Blood Spot (DBS) EIA is an in-vitro quantitative limiting antigen (LAg) avidity enzyme immunoassay for distinguishing recent HIV-1 infections from those which are long-term. Persons with recently acquired HIV-1 infections typically exhibit HIV-1 specific IgG populations with higher proportions of lower avidity IgG than those with long-term infections ...
The Maxim Swift HIV Recent Infection Assay (RIA) is a single use qualitative immunoassay to detect the circulating antibodies to Human Immunodeficiency Virus Type 1 (HIV-1), Type 2 (HIV-2) and distinguish between recent and long-term infection in HIV-1/2. The assay is a point of care (POC) test intended for use with blood or serum/ plasma specimens. The Maxim Swift™ HIV RIA uses US CDC ...
The Maxim Swift HIV Recent Infection Assay (RIA) is a single use qualitative immunoassay to detect the circulating antibodies to Human Immunodeficiency Virus Type 1 (HIV-1), Type 2 (HIV-2) and distinguish between recent and long-term infection in HIV-1/2. The assay is a point of care (POC) test intended for use with blood or serum/ plasma specimens. The Maxim Swift™ HIV RIA uses US CDC ...
Clinical Trials Typically, there are three phases of clinical trials. Vaccines that are being developed for children are first tested in adults. ...